Nova Eye Medical Limited (ELXMF)
Nova Eye Medical Limited operates in the Medical - Devices industry of the Healthcare sector, headquartered in Kent Town, SA, AU. The stock last traded at $0.01, up 0.00% on the session, giving a market capitalisation of $4.1M. On trailing twelve-month figures it carries a trailing P/E of -6.05, a net margin of -21.3%. Its beta of 0.93 implies it has historically moved less than the broad market.
Headquartered in Kent Town, Australia, and established in 1985, Nova Eye Medical Limited is dedicated to the development, manufacturing, and global commercialization of surgical solutions for eye conditions, with a primary focus on glaucoma. Their product lineup features the iTrack surgical system, engineered to reduce intraocular pressure in adult patients with open-angle glaucoma, alongside its evolution, iTrack Advance, which promotes natural ocular fluid drainage. For individuals with severe or intricate forms of glaucoma, they provide the Molteno3 drainage device. Additionally, the company offers 2RT, a unique laser technology aimed at treating early to intermediate age-related macular degeneration. Nova Eye Medical Limited maintains a significant international footprint, conducting operations across Australia, the United States, Europe, and the Asia Pacific region. The company officially adopted its current name in July 2020, having previously operated as Ellex Medical Lasers Limited.
Nova Eye Medical Limited is most often compared with the following Healthcare names: